Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms
Open Access
- 28 January 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (4) , 820-826
Abstract
Microbial adhesion and biofilms have important implications for human health and disease. Candida albicans is an opportunistic pathogen which forms drug-resistant biofilms that contribute to the recalcitrance of disease. We have developed a high-throughput screen for potentiators of clotrimazole, a common therapy for Candida infections, including vaginitis and thrush. The screen was performed against C. albicans biofilms grown in microtitre plates in order to target the most resilient forms of the pathogen. Biofilm growth, in individual wells of 384-well plates, was measured using the metabolic indicator alamarBlue® and found to be very consistent and reproducible. This assay was used to test the effect of more than 120 000 small molecule compounds from the NIH Molecular Libraries Small Molecule Repository, and compounds that enhanced the activity of clotrimazole or acted on the biofilms alone were identified as hits. Nineteen compounds (0.016% hit rate) were identified and found to cause more than 30% metabolic inhibition of biofilms compared with clotrimazole alone, which had a modest effect on biofilm viability at the concentration tested. Hits were confirmed for activity against biofilms with dose–response measurements. Several compounds had increased activity in combination with clotrimazole, including a 1,3-benzothiazole scaffold that exhibited a >100-fold improvement against biofilms of three separate C. albicans isolates. Cytotoxicity experiments using human fibroblasts confirmed the presence of lead molecules with favourable antifungal activity relative to cytotoxicity. We have validated a novel approach to identify antifungal potentiators and completed a high-throughput screen to identify small molecules with activity against C. albicans biofilms. These small molecules may specifically target the biofilm and make currently available antifungals more effective.Keywords
This publication has 46 references indexed in Scilit:
- Candida albicans forms biofilms on the vaginal mucosaMicrobiology, 2010
- Interaction of Candida albicans Biofilms with Antifungals: Transcriptional Response and Binding of Antifungals to Beta-GlucansAntimicrobial Agents and Chemotherapy, 2010
- Patients with Long-Term Oral Carriage Harbor High-Persister Mutants of Candida albicansAntimicrobial Agents and Chemotherapy, 2010
- Characterization of Mucosal Candida albicans BiofilmsPLOS ONE, 2009
- Hsp90 Orchestrates Stress Response Signaling Governing Fungal Drug ResistancePLOS Pathogens, 2009
- ABC Transporter Cdr1p Contributes More than Cdr2p Does to Fluconazole Efflux in Fluconazole-Resistant Candida albicans Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2008
- Characterization of Three Classes of Membrane Proteins Involved in Fungal Azole Resistance by Functional Hyperexpression inSaccharomyces cerevisiaeEukaryotic Cell, 2007
- Role for Cell Density in Antifungal Drug Resistance in Candida albicans BiofilmsAntimicrobial Agents and Chemotherapy, 2007
- Putative Role of β-1,3 Glucans in Candida albicans Biofilm ResistanceAntimicrobial Agents and Chemotherapy, 2007
- Candida albicans Biofilms Produce Antifungal-Tolerant Persister CellsAntimicrobial Agents and Chemotherapy, 2006